Exchange: NASDAQ·Updated 10:41 AM EDT

VKTX News

News
all
press releases
4 Biotech Stocks to Watch as Potential Takeover Targets
Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
Zacks
More News
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?
LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.
Zacks
Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?
NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.
Zacks
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $29.52, representing a -1.44% change from its previous close.
Zacks
What's Going On With the Dip in Viking Therapeutics Stock?
Viking Therapeutics shares are dropping Tuesday amid a risk-off trade, though its longer-term uptrend and sector strength both remain intact.read more...
Benzinga
Can Viking Therapeutics Beat Big Pharma With Monthly Weight-Loss Shots? Here’s The Risk CEO Says Could Derail It
CEO Brian Lian said monthly VK2735 must preserve weight loss without restarting nausea, vomiting and other gastrointestinal effects.
Stocktwits
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.
Zacks
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Zacks
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.13, moving 1.74% from the previous trading session.
Zacks
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAxsome Therapeutics has transitioned into a commercial-stage entity with rapidly growing revenue from its central nervous system treatments...
Nasdaq News: Markets

Advertisement|Remove ads.